Abstract
Introduction. Immunomodulatory medicinal plants have been extensively investigated in vitro, in animal models, and in human studies. Aromatic and essential oil–containing species, including Laurus nobilis, Nigella sativa, Withania somnifera, Echinacea purpurea, and Andrographis paniculata, comprise bioactive phytochemicals such as terpenoids, flavonoids, and phenolic compounds that influence both innate and adaptive immune responses. Aim of the study. This review aimed to provide a translational analysis of mechanistic, preclinical, and clinical evidence supporting their immunomodulatory potential. Methodology. A comprehensive literature search was conducted using PubMed, Scopus, and Web of Science, focusing on experimental and human studies reporting immunological outcomes. Discussion. Preclinical investigations demonstrate that plant-derived compounds modulate macrophage activation, cytokine expression, lymphocyte proliferation, and natural killer (NK) cell activity. For example, andrographolide influences T-cell signalling and cytokine production, while thymoquinone enhances NK cell cytotoxicity and regulates Th1/Th2 balance. Translational human studies report increased lymphocyte counts and cytokine levels following supplementation with standardised extracts. Randomised controlled trials further indicate that Withania somnifera enhances immunoglobulins, T helper cells, and NK cell activity. Echinacea purpurea increases NK cytotoxicity and cytokine production, and Allium-based formulations reduce the incidence and severity of respiratory infections in older adults. From a pharmacological perspective, these plants act as multi-target agents modulating signalling cascades and gene expression. However, variability in extract standardisation, dosage regimens, and bioavailability contributes to heterogeneity in clinical outcomes. Conclusion. Overall, medicinal plants demonstrate regulatory rather than purely stimulatory immune effects, supporting their potential role in integrative immunotherapy. Further large-scale, well-controlled trials using standardised preparations are required to strengthen clinical translation.

This publication has 20 references indexed in Scilit: